贝林妥欧单抗桥接CAR-T细胞治疗成人急性B淋巴细胞白血病的临床疗效与安全性
回顾性分析苏州大学附属第一医院2018年8月至2023年5月36例成人B-ALL患者,18例接受贝林妥欧单抗桥接CAR-T、18例仅接受CAR-T。桥接组桥接后1个月CR率100.0%,MRD阴性率94.4%高于非桥接组61.1%(P=0.041),CRS等不良反应发生率11.1%低于非桥接组50.0%(P=0.027),1年总生存率在0.1水平有统计学差异。
要点
- 贝林妥欧单抗桥接CAR-T组桥接后1个月CR率100.0%,MRD阴性率94.4%。
- 桥接组MRD阴性率高于非桥接组(94.4%对61.1%,P=0.041)。
- 桥接组CRS及其他不良反应发生率低于非桥接组(11.1%对50.0%,P=0.027)。
核心结论
- 贝林妥欧单抗桥接CAR-T细胞治疗成人B-ALL疗效及安全性值得肯定,清除肿瘤残留效果好,近期疗效复发率低,不良反应少。
- 长期疗效仍在随访评估中。
研究设计与样本
- 回顾性分析2018年8月至2023年5月在苏州大学附属第一医院住院治疗的36例成人B-ALL患者临床资料。
- 男18例、女18例,中位年龄43.5(21~72)岁;费城染色体阳性急性淋巴细胞白血病21例,复发/难治16例。
- 18例接受贝林妥欧单抗桥接CAR-T细胞治疗,18例仅接受CAR-T细胞治疗,分析两组疗效及安全性。
主要发现
- 贝林妥欧单抗桥接CAR-T组中16例贝林妥欧单抗治疗后获完全缓解,CR率88.9%。
- 桥接CAR-T治疗1个月后复查骨髓象,CR率100.0%,MRD阴性率高于非桥接组(94.4%对61.1%,Fisher,P=0.041)。
- 桥接组CRS及其他不良反应发生率低于非桥接组(11.1%对50.0%,Fisher,P=0.027)。
- 截至随访终点,桥接组13例持续MRD阴性,5例在治疗后2.57~10.20个月复发,2例复发患者接受第二次CAR-T细胞治疗后达CR。
- 非桥接组10例持续MRD阴性、7例复发、6例死亡;桥接组1年总生存率高于非桥接组[(88.9±10.5)%对(66.7±10.9)%,P=0.091],差异在0.1水平有统计学意义。
关键数值与推荐
- 桥接组贝林妥欧单抗治疗后CR率88.9%(16例)。
- 桥接后1个月CR率100.0%;MRD阴性率桥接组94.4%对非桥接组61.1%(Fisher,P=0.041)。
- CRS及其他不良反应发生率桥接组11.1%对非桥接组50.0%(Fisher,P=0.027)。
- 1年总生存率桥接组(88.9±10.5)%对非桥接组(66.7±10.9)%,P=0.091,差异在0.1水平有统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: Exploring the efficacy and safety of bridging blinatumomab (BiTE) in combination with chimeric antigen receptor T (CAR-T) cell therapy for the treatment of adult patients with acute B-cell lymphoblastic leukemia (B-ALL) . Methods: Clinical data from 36 adult B-ALL patients treated at the First Affiliated Hospital of Suzhou University from August 2018 to May 2023 were retrospectively analyzed. A total of 36 cases were included: 18 men and 18 women. The median age was 43.5 years (21-72 years). Moreover, 21 cases of Philadelphia chromosome-positive acute lymphoblastic leukemia were reported, and 16 of these cases were relapsed or refractory. Eighteen patients underwent blinatumomab bridging followed by CAR-T cell therapy, and 18 patients received CAR-T cell therapy. This study analyzed the efficacy and safety of treatment in two groups of patients. Results: In the BiTE bridge-to-CAR-T group, 16 patients achieved complete remission (CR) after BiTE immunotherapy, with a CR rate of 88.9%. One month after bridging CAR-T therapy, bone marrow examination showed a CR rate of 100.0%, and the minimal residual disease (MRD) negativity rate was higher than the nonbridging therapy group (94.4% vs. 61.1%, Fisher, P=0.041). The incidence of cytokine release syndrome and other adverse reactions in the BiTE bridge-to-CAR-T group was lower than that in the nonbridging therapy group (11.1% vs. 50.0%, Fisher, P=0.027). The follow-up reveals that 13 patients continued to maintain MRD negativity, and five patients experienced relapse 8.40 months (2.57-10.20 months) after treatment. Two of five patients with relapse achieved CR after receiving the second CAR-T cell therapy. In the nonbridging therapy group, 10 patients maintained continuous MRD negativity, 7 experienced relapse, and 6 died. The 1 year overall survival rate in the BiTE bridge-to-CAR-T group was higher than that in the nonbridging therapy group, with a statistically significant difference at the 0.1 level (88.9%±10.5% vs. 66.7%±10.9%, P=0.091) . Conclusion: BiTE bridging CAR-T cell therapy demonstrates excellent efficacy in adult B-ALL treatment, with a low recent recurrence rate and ongoing assessment of long-term efficacy during follow-up. 目的: 探讨贝林妥欧单抗桥接嵌合抗原受体T(CAR-T)细胞疗法治疗急性B淋巴细胞白血病(B-ALL)患者的疗效及安全性。 方法: 回顾性分析2018年8月至2023年5月在苏州大学附属第一医院住院治疗的36例成人B-ALL患者的临床资料。男18例,女18例,中位年龄为43.5(21~72)岁。其中费城染色体阳性急性淋巴细胞白血病(Ph(+)ALL)21例,复发/难治16例。18例患者接受贝林妥欧单抗桥接CAR-T细胞治疗,18例患者仅接受CAR-T细胞治疗,分析两组患者的疗效及安全性。 结果: 贝林妥欧单抗桥接CAR-T组中16例患者贝林妥欧单抗治疗后获得完全缓解(CR),CR率88.9%。桥接CAR-T治疗1个月后复查骨髓象,CR率为100.0%,微小残留病(MRD)阴性率高于未接受贝林妥欧单抗桥接治疗组(94.4%对61.1%,Fisher,P=0.041)。贝林妥欧单抗桥接CAR-T组患者细胞因子释放综合征(CRS)及其他不良反应发生率低于未接受贝林妥欧单抗桥接治疗组(11.1%对50.0%,Fisher,P=0.027)。截至随访终点,贝林妥欧单抗桥接CAR-T组中13例患者持续MRD阴性状态,5例患者(包含2例经贝林妥欧单抗治疗无效的病例)在治疗后2.57~10.20个月复发,2例复发患者后续接受第二次CAR-T细胞治疗后达CR。未接受贝林妥欧单抗桥接治疗组中10例患者持续MRD阴性状态,7例复发,6例死亡。贝林妥欧单抗桥接CAR-T组患者1年总生存率高于未接受桥接治疗组,差异在0.1水平有统计学意义[(88.9±10.5)%对(66.7±10.9)%,P=0.091]。 结论: 贝林妥欧单抗桥接CAR-T细胞治疗成人B-ALL疗效及安全性值得肯定,清除肿瘤残留效果好,近期疗效复发率低,不良反应少。.
引用
- Pu Y, Zhou XY, Liu Y, et al. [Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 38951060. doi:10.3760/cma.j.cn121090-20231127-00283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。